MarketCap
Facebook
X
TelegramZogenix, Inc. Total Assets 2011-2025 | ZGNX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Zogenix, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 651 M | 414 M | 648 M | 418 M | 232 M | 306 M | 203 M | 113 M | 80.7 M | 101 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 651 M | 80.7 M | 317 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Autolus Therapeutics plc
AUTL
|
783 M | $ 1.92 | 14.97 % | $ 490 M |  Britain |
 |
Aclaris Therapeutics
ACRS
|
220 M | $ 3.02 | -0.5 % | $ 233 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.09 | -2.52 % | $ 7.43 B |  Australia |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Aptorum Group Limited
APM
|
16.1 M | $ 1.11 | -2.62 % | $ 6.05 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
608 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
1.18 B | $ 211.4 | 1.16 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
 |
BioVie
BIVI
|
21.6 M | $ 1.18 | -2.89 % | $ 1.74 M | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
325 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
60.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
23.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Catalyst Biosciences
CBIO
|
117 M | $ 12.42 | 0.57 % | $ 818 M | USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
283 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.12 M | $ 0.17 | -20.57 % | $ 370 M |  Israel |
 |
Berkeley Lights
BLI
|
226 M | - | -7.31 % | $ 87 M | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
22.5 B | $ 95.2 | 0.72 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
1.58 B | $ 26.96 | -0.59 % | $ 1.31 B | USA |
 |
Certara
CERT
|
1.58 B | $ 8.85 | -0.51 % | $ 1.42 B | USA |
 |
BeiGene, Ltd.
BGNE
|
5.92 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
64.8 M | - | -10.95 % | $ 876 K | USA |
 |
Anika Therapeutics
ANIK
|
271 M | $ 9.53 | -0.21 % | $ 140 M | USA |
 |
bluebird bio
BLUE
|
619 M | - | - | $ 546 M | USA |
 |
Cellectis S.A.
CLLS
|
384 M | $ 4.93 | 3.79 % | $ 116 M | France |
 |
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
4.47 B | $ 581.87 | -0.34 % | $ 44.1 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.55 | 4.08 % | $ 16 M | USA |
 |
AstraZeneca PLC
AZN
|
104 B | $ 92.76 | -0.15 % | $ 96.9 B | Britain |
 |
ChromaDex Corporation
CDXC
|
68.3 M | - | -0.88 % | $ 598 M | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
3.11 B | $ 9.25 | 1.82 % | $ 1.49 B | Britain |
 |
CorMedix
CRMD
|
82.1 M | $ 12.74 | 1.66 % | $ 649 M | USA |
 |
Celldex Therapeutics
CLDX
|
792 M | $ 25.91 | -1.87 % | $ 1.67 M | USA |